Relaxation dynamics and frequency response of a noisy cell signaling network.

We investigate the dynamics of cell signaling using an experimentally based Boolean model of the human fibroblast signal transduction network. We determine via systematic numerical simulations the relaxation dynamics of the network in response to a constant set of inputs, both in the absence and in the presence of environmental fluctuations. We then study the network's response to periodically modulated signals, uncovering different types of behaviors for different pairs of driven input and output nodes. The phenomena observed include low-pass, high-pass, and band-pass filtering of the input modulations, among other nontrivial responses, at frequencies around the relaxation frequency of the network. The results reveal that the dynamic response to the external modulation of biologically realistic signaling networks is versatile and robust to noise.

Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

We undertook this study to examine the accuracy of plasma C-peptide as a marker of insulin secretion. The peripheral kinetics of biosynthetic human C-peptide (BHCP) were studied in 10 normal volunteers and 7 insulin-dependent diabetic patients. Each subject received intravenous bolus injections of BHCP as well as constant and variable rate infusions. After intravenous bolus injections the metabolic clearance rate of BHCP (3.8 +/- 0.1 ml/kg per min, mean +/- SEM) was not significantly different from the value obtained during its constant intravenous infusion (3.9 +/- 0.1 ml/kg per min). The metabolic clearance rate of C-peptide measured during steady state intravenous infusions was constant over a wide concentration range. During experiments in which BHCP was infused at a variable rate, the peripheral concentration of C-peptide did not change in proportion to the infusion rate. Thus, the infusion rate of BHCP could not be calculated accurately as the product of the C-peptide concentration and metabolic clearance rate. However, the non-steady infusion rate of BHCP could be accurately calculated from peripheral C-peptide concentrations using a two-compartment mathematical model when model parameters were derived from the C-peptide decay curve in each subject. Application of this model to predict constant infusions of C-peptide from peripheral C-peptide concentrations resulted in model generated estimates of the C-peptide infusion rate that were 101.5 +/- 3.4% and 100.4 +/- 2.8% of low and high dose rates, respectively. Estimates of the total quantity of C-peptide infused at a variable rate over 240 min based on the two-compartment model represented 104.6 +/- 2.4% of the amount actually infused. Application of this approach to clinical studies will allow the secretion rate of insulin to be estimated with considerable accuracy. The insulin secretion rate in normal subjects after an overnight fast was 89.1 pmol/min, which corresponds with a basal 24-h secretion of 18.6 U.

Reevaluation of urine C-peptide as measure of insulin secretion.

Urine C-peptide (UCP) has been proposed as a measure of insulin secretion, because insulin and C-peptide are consecreted in equimolar concentrations by the pancreatic beta-cell. The validity of this approach was tested by comparing insulin secretion rates, calculated by application of a two-compartmental analysis of peripheral C-peptide concentrations, with UCP excretion rates. Insulin secretion and UCP excretion with subjects on a mixed diet were simultaneously measured over a 24-h period in 13 patients with noninsulin-dependent diabetes mellitus and in 14 matched nondiabetic control subjects. The fraction of secreted C-peptide that was excreted in the urine (fractional C-peptide excretion) showed considerable intersubject variability in the diabetic (11.3 +/- 1.6%, range 3.9-20.8) and control (8.0 +/- 1.7%, range 1.1-27.9, P = .07) subjects (means +/- SE). UCP clearance demonstrated a similar degree of variability and was not significantly different (P = .07) between diabetic (23.8 +/- 3.0 ml/min) and control (16.5 +/- 2.7 ml/min) subjects. In control subjects, the 24-h insulin secretion rate correlated more closely with the fasting insulin secretion rate (r = .97, P = .0001), fasting C-peptide (r = .81, P = .0005), and fasting insulin (r = .80, P = .0005) concentrations than with the 24-h UCP excretion rate (r = .62, P = .02). Similar results were obtained in the diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)

A radioimmunoassay for circulating human proinsulin.

A radioimmunoassay for human proinsulin (hPl) has been developed using biosynthetic hPl prepared by recombinant DNA technology as immunogen, standard, and tracer. The antiserum was raised in a guinea pig and then adsorbed against insulin and C-peptide conjugated to Sepharose to improve its specificity. After adsorption of the antiserum, the cross-reactivities to insulin and C-peptide were each less than 0.2%. Competition studies using in vitro enzymatically split forms of proinsulin demonstrated that the major antigenic determinant recognized was the junctional region between the B-chain of insulin and the C-peptide. The range of the assay extended from 10 to 150 fmol/tube, with a 50% displacement of 45-55 fmol/tube. This sensitivity proved suitable for measurements of serum hPl concentrations during infusion of biosynthetic hPl into normal subjects and type I diabetic subjects. Eighty-five of 89 serum samples from the normal subjects and each of 20 samples from diabetic subjects diluted in parallel with the hPl standard. Since the direct assay sensitivity was not sufficient for measurement of endogenous hPl levels, a simple procedure for quantitative extraction of proinsulin-like material (PLM) from up to 40 ml of plasma on insulin antibody-Sepharose columns was developed. Logit-log slopes were calculated for dilutions of extracts of samples collected in the fasting state and 60 min after 75 g or oral glucose from eight healthy subjects. The slopes of 15 of the 16 samples did not differ significantly from the slope of the hPl standard.(ABSTRACT TRUNCATED AT 250 WORDS)

Binding of nuclear triiodothyronine (T3) binding protein-T3 complex to chromatin.

Nuclear tirrodothyronine (T3) binding protein (NTBP)-T3 complex, prepared from liver nuclei of rats given [125I]T3 in vovo, rebinds to rat nuclear chromatin at pH 7.4 and at low, but not high, KCl concentrations. Liver NTBP-T3 complex binds to chromatin from liver, kidney, heart, brain, testis, and spleen. Binding was depressed at pH8, by addition of 10 mm CaCl2 or 100 mM MgCl2, and by 1 mM GTP or UTP. Although heart chromatin bound the most NTBP-T3 complex and brain the least, there is no clear separation of binding activity on comparison of three T3-responsive tissues (heart, liver, kidney) to the T3 insensitive tissues. Under the conditions of these experiments, there was no evident competition for binding sites on any of the six chromatins tested.

Thyroid hormone increases type I adenosine 3', 5'-monophosphate-dependent protein kinase and casein kinase activities in rat liver cytosol: analysis of protein kinases by polyacrylamide disc gel electrophoresis.

We investigated the action of thyroid hormone on each protein kinase in rat liver cytosol. Kinases were analyzed by polyacrylamide disc gel electrophoresis and isoelectric focusing in polyacrylamide gel. Polyacrylamide disc gel electrophoresis separated cAMP-dependent protein kinase type I (Rf = 0.35), type II (Rf = 0.44), their catalytic subunit (Rf = 0.26), and cAMP-independent protein kinase (Rf = 0.50). Casein kinase was detected at Rf = 0.37. In addition to the catalytic subunit with Rf = 0.26, another catalytic subunit was found at Rf = 0.44 when the cytosol was preincubated with cAMP. The administration of T3 (20 micrograms/100 g BW for 3 days) to hypothyroid rats increased enzyme activities of type I holoenzyme and casein kinase by 48%. Free catalytic subunit, separated from holoenzyme, had the same level of enzyme activity in both groups, suggesting greater endogenous dissociation of type I holoenzyme in hypothyroid rats. When heat-inactivated rat liver cytosol was used as substrate in the assay of protein kinase activity, the peak enzyme active in phosphorylating the cytosol corresponded to the casein kinase peak. Our data indicate that casein kinase is the main enzyme that mediates phosphorylation of endogenous proteins in rat liver cytosol, and that T3 treatment increases the activity of casein kinase and of type I cAMP-dependent protein kinase.

Triiodothyronine receptors during maturation.

Capacity of rat liver nuclear triiodothyronine (T3) binding protein (NTBP) for T3 more than quadruples from birth through 50-120 days, whether related to DNA or weight of tissue. Ka for T3 doubles during this interval. T3 content of nuclei nearly parallels capacity. The proportion of receptors occupied by T3 is 0.3 at birth, falling to .16 in old rats. In contrast to these changes in liver content of T3-receptor complex, mitochondrial alpha-glycerophosphate dehydrogenase activity changes relatively less during maturation. Administration of estrogen, testosterone, and dexamethasone to immature female rats did not alter NTBP capacity of affinity.

Roentgenographic contrast agents inhibit triiodothyronine binding to nuclear receptors in vitro.

The ability of roentgenographic contrast agents to inhibit binding of [125I]T3 to nuclear receptors was studied during incubation of rat liver nuclei or nuclear extracts in vitro and after ip administration of the agents in vivo. Ipodate, iodipamide, iopanoic acid, and diatrizoate inhibited binding of [125I]T3 in vitro. The most potent inhibitor was ipodate, which produced 50% inhibition of binding at 1.2 X 10(-4) M. When given orally in acute in vivo experiments, ipodate did not diminish binding to liver nuclear receptors. Ipodate appeared to inhibit in vivo metabolism of [125I]T3.

Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia.

Two new radioimmunoassays for human proinsulin (hPI) have been developed and used to study patients with islet cell tumors and familial hyperproinsulinemia. Both antisera were adsorbed against human C-peptide conjugated to Sepharose, following which cross-reactivity to insulin and C-peptide was less than 0.001%. Antiserum 18D recognized the junction between the insulin B-chain and C-peptide and provided fivefold greater sensitivity than our previously reported hPI assay. Antiserum 11E recognized a determinant which includes or is adjacent to the A-chain-C-peptide junction or which is specified by the tertiary structure. In all 20 patients studied with surgically confirmed islet cell tumors, fasting plasma proinsulinlike material (PLM) was abnormal (greater than 3 SD from the mean measured in either lean or obese subjects) in both assays. This provided better discrimination than has been reported for PLM measured by gel filtration (abnormal in 13 of 14 of the present samples) with a considerably less laborious procedure. Samples from two families in which a mutant proinsulin is present in the circulation have immunoreactivity in the two assays consistent with previous identification of the molecule as an A-chain-C-peptide-linked intermediate of proinsulin conversion. The immunoreactivity of a sample from another family in which large amounts of proinsulin circulate are consistent with an intact molecule being the predominant form. This assay will be useful for confirming the diagnosis of insulin-secreting tumor in patients suspected of recurrent fasting hypoglycemia and in physiologic studies of proinsulin secretion.

Time-dependent deformation of some direct compression excipients.

Three techniques were used to compare the time-dependent deformation of microfine cellulose (Elcema G250), anhydrous lactose, dicalcium phosphate dihydrate (Emcompress), modified starch (Sta-Rx 1500) and sodium chloride. (1) In stress-relaxation experiments using a reciprocating tablet machine, none of the materials behaved as a Maxwell body in contrast to recent published work (David & Augsburger, 1977). Possible reasons for this disagreement are discussed. (2) Heckel plots showed that increasing the time for which a material was under compression (contact times of 0.17 and 10 s) had no effect on dicalcium phosphate compacts but increased the consolidation of other materials in the rank order sodium chloride less than lactose less than cellulose less than starch. (3) Deformation tests on preformed compacts were carried out in diametral compression by loading compacts to 75% of their breaking force at four different strain rates between 0.05 and 6.5 mm min-1. The deformation of Sta-Rx compacts was time-dependent. Sodium chloride compacts exhibited brittle behaviour in the diametral compression test and in the 10 s contact time experiment. This was apparently due to work-hardening, following the extensive plastic deformation of crystals during compaction as indicated by the stress relaxation results.

Integration of cellular signals in chattering environments.

Cells are constantly exposed to fluctuating environmental conditions. External signals are sensed, processed and integrated by cellular signal transduction networks, which translate input signals into specific cellular responses by means of biochemical reactions. These networks have a complex nature, and we are still far from having a complete characterization of the process through which they integrate information, specially given the noisy environment in which that information is embedded. Guided by the many instances of constructive influences of noise that have been reported in the physical sciences in the last decades, here we explore how multiple signals are integrated in an eukaryotic cell in the presence of background noise, or chatter. To that end, we use a Boolean model of a typical human signal transduction network. Despite its complexity, we find that the network is able to display simple patterns of signal integration. Furthermore, our computational analysis shows that these integration patterns depend on the levels of fluctuating background activity carried by other cell inputs. Taken together, our results indicate that signal integration is sensitive to environmental fluctuations, and that this background noise effectively determines the information integration capabilities of the cell.

Pathophysiologic control of nuclear triiodothyronine receptor capacity.

Mechanisms involved in the reduced T3 receptor capacity found in a variety of pathophysiologic states were investigated by in vitro assessment of T3 receptor-nuclei interaction using tissue prepared from rats. In nuclei from immature animals, nuclear uptake of receptor was reduced, release was accelerated, and these alterations could account for the reduced nuclear receptor capacity. The functions reached the normal adult condition by 30-50 days. Nuclei from animals starved for 72 h showed no change in release of receptor, a 15% decrease in uptake, and 48% decrease in total binding capacity, indicating that the major effect is related to diminished supply of receptor, presumably due to reduced synthesis in the extranuclear compartment. Glucagon administration produced no change in receptor release, 25% decrease in receptor uptake, and nearly equivalent 33% decrease in binding capacity. Alteration in receptor uptake could account largely for changes induced by glucagon. Animals studied 24 h after hepatectomy had a 53% decrease in total binding capacity, but no change in uptake or release, indicating that reduced receptor synthesis is the primary abnormality. Administration of alpha-amanitin caused a 30% diminution in the binding capacity in the nuclei, without change in uptake and release, and cycloheximide caused an 87% decrease in binding capacity, with minimal change in uptake and no change in release. In both instances the alterations are interpretable as diminished synthesis and availability of receptor, rather than alterations in binding receptor to chromatin. The major cause of diminished receptor capacity appears to be reduced cytosolic synthesis of receptor, with reduction in retention by chromatin-associated factors playing a significant role in immature animals, and during glucagon treatment.